Literature DB >> 21841248

γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib.

Charlotte Bauer1, Raphaëlle Pardossi-Piquard, Julie Dunys, Maggie Roy, Frédéric Checler.   

Abstract

Proteolytic degradation has emerged as a key pathway involved in controlling levels of the Alzheimer's disease (AD)-associated amyloid-β peptides (Aβ) in the brain. The ectopeptidase, neprilysin (NEP), has been reported as the major Aβ-degrading enzyme in mice and human brains. We have previously shown that NEP expression and activity are regulated by AICD, the intracellular domain of the amyloid-β protein precursor (AβPP) generated by γ-secretase. Thus, NEP transcription, expression, and enzymatic activity are dramatically reduced in fibroblasts devoid of AβPP (the precursor of AICD) or lacking both presenilin (PS) 1 and 2 (two parent proteins contributing to AICD formation). We demonstrate here that NEP expression and activity are influenced by a number of cell passages and density, and we confirm a drastic reduction of NEP expression and activity in AβPP and PS null fibroblasts examined at similar passages and cell densities. Furthermore, Imatinib (Gleevec), a known tyrosine kinase inhibitor was recently shown to elevate AICD in H4 human neuroglioma cells, and this was accompanied by concomitant increases of NEP protein, mRNA levels, and activity. However, the demonstration of a causal link between Imatinib and AICD levels was still lacking. We show here an Imatinib-dependent effect on NEP expression and activity in murine fibroblasts and establish that Imatinib-induced modulation of NEP was abolished by the depletion of AβPP or its homologues APLP1 and APLP2, thereby confirming that Imatinib-mediated control of NEP could indeed be accounted for its effect on AICD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21841248     DOI: 10.3233/JAD-2011-110746

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  13 in total

Review 1.  Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy.

Authors:  Natalia N Nalivaeva; Anthony J Turner
Journal:  Br J Pharmacol       Date:  2019-03-11       Impact factor: 8.739

Review 2.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

3.  The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation.

Authors:  Ishrut Hussain; Julien Fabrègue; Laurence Anderes; Solenne Ousson; Frédéric Borlat; Valérie Eligert; Sébastien Berger; Mitko Dimitrov; Jean-René Alattia; Patrick C Fraering; Dirk Beher
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

Review 4.  Electroosmotic perfusion of tissue: sampling the extracellular space and quantitative assessment of membrane-bound enzyme activity in organotypic hippocampal slice cultures.

Authors:  Yangguang Ou; Juanfang Wu; Mats Sandberg; Stephen G Weber
Journal:  Anal Bioanal Chem       Date:  2014-08-29       Impact factor: 4.142

5.  The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?

Authors:  N N Nalivaeva; N D Belyaev; I A Zhuravin; A J Turner
Journal:  Int J Alzheimers Dis       Date:  2012-07-26

6.  The amyloid precursor protein intracellular domain-fe65 multiprotein complexes: a challenge to the amyloid hypothesis for Alzheimer's disease?

Authors:  Daniel A Bórquez; Christian González-Billault
Journal:  Int J Alzheimers Dis       Date:  2012-02-09

7.  Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.

Authors:  Bikash R Sahoo; Pritam Kumar Panda; Wenguang Liang; Wei-Jen Tang; Rajeev Ahuja; Ayyalusamy Ramamoorthy
Journal:  J Mol Biol       Date:  2021-04-16       Impact factor: 6.151

8.  APP intracellular domain derived from amyloidogenic β- and γ-secretase cleavage regulates neprilysin expression.

Authors:  Marcus O W Grimm; Janine Mett; Christoph P Stahlmann; Sven Grösgen; Viola J Haupenthal; Tamara Blümel; Benjamin Hundsdörfer; Valerie C Zimmer; Nadine T Mylonas; Heikki Tanila; Ulrike Müller; Heike S Grimm; Tobias Hartmann
Journal:  Front Aging Neurosci       Date:  2015-05-19       Impact factor: 5.750

9.  Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau.

Authors:  Yang Hong-Qi; Sun Zhi-Kun; Chen Sheng-Di
Journal:  Transl Neurodegener       Date:  2012-10-30       Impact factor: 8.014

10.  Epigenetic induction of EGR-1 expression by the amyloid precursor protein during exposure to novelty.

Authors:  Aurélie Hendrickx; Nathalie Pierrot; Bernadette Tasiaux; Olivier Schakman; Jean-Pierre Brion; Pascal Kienlen-Campard; Charles De Smet; Jean-Noël Octave
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.